Vulvovaginal Candidiasis (VVC): Market View
Description
Vulvovaginal Candidiasis (VVC): Market View
Summary
This reports provides a data-driven overview of the current and future competitive landscape in VVC Therapeutics.
In 2024 and 2029, China is anticipated to have the highest number of lifetime diagnosed prevalent cases of VVC, representing a large portion of global cases. In 2024.
Currently, the VVC market is saturated with generic drugs, and the lanosterol 14 alpha demethylase inhibitor drug class dominates the approved innovator drugs to treat VVC.
The VVC pipeline holds nine molecules, with one asset in the pre-registration stage and another four in Phase II.
Over the past decade, 183 clinical trials have been conducted in VVC. The year with the most studies initiated was 2023, with 30 trials, followed by 2019, with 24 trials.
During the past 18 months, five mergers and acquisitions and one strategic alliance involving companies developing VVC assets were completed globally.
Scope
GlobalData’s VVC: Market View combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.
Components of the report include -
Summary
This reports provides a data-driven overview of the current and future competitive landscape in VVC Therapeutics.
In 2024 and 2029, China is anticipated to have the highest number of lifetime diagnosed prevalent cases of VVC, representing a large portion of global cases. In 2024.
Currently, the VVC market is saturated with generic drugs, and the lanosterol 14 alpha demethylase inhibitor drug class dominates the approved innovator drugs to treat VVC.
The VVC pipeline holds nine molecules, with one asset in the pre-registration stage and another four in Phase II.
Over the past decade, 183 clinical trials have been conducted in VVC. The year with the most studies initiated was 2023, with 30 trials, followed by 2019, with 24 trials.
During the past 18 months, five mergers and acquisitions and one strategic alliance involving companies developing VVC assets were completed globally.
Scope
GlobalData’s VVC: Market View combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.
Components of the report include -
- Disease Landscape
- Disease Overview
- Epidemiology Overview
- Treatment Overview
- Marketed Products Assessment
- Breakdown by Mechanism of Action, Route of Administration
- Product Profiles with Sales Forecast
- Pricing and Reimbursement Assessment
- Annual Therapy Cost
- Time to Pricing and Time to Reimbursement
- Pipeline Assessment
- Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
- Product Profiles with Sales Forecast
- Late-to-mid-stage Pipeline Drugs
- Phase Transition Success Rate and Likelihood of Approval
- Clinical Trials Assessment
- Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
- Enrolment Analytics, Site Analytics, Feasibility Analysis
- Deals Landscape
- Mergers, Acquisitions, and Strategic Alliances by Region
- Overview of Recent Deals
- Commercial Assessment
- Key Market Players
- Future Market Catalysts
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the VVC Therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, and companies likely to impact the global VVC Therapeutics market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories that present the maximum opportunities for consolidations, investments, and strategic partnerships.
Table of Contents
85 Pages
- Report Scope
- Key Findings
- Disease Etiology
- Epidemiology Overview - Lifetime Diagnosed Prevalent Cases of VVC in 2024 and 2029
- Treatment Overview
- Marketed Drugs - Leading Marketed Drugs in VVC
- Marketed Drugs - Overview of Drugs by Approval and Drug Type
- Marketed Drugs - Overview by MOA
- Marketed Drug Profile - Scynexis' Brexafemme/Hengmeida
- Marketed Drug Profile - Mycovia Pharmaceuticals' Vivjoa
- Marketed Drug Profile - Bayer's Gynotran/Neo-Penotran Forte
- Marketed Drug Profile - Sanofi's Flagyl/Flagystatin
- Marketed Drug Profile - Italmex's Macmiror Complex V
- Marketed Drug Profile - Bayer's Canesoral/Canesoral Duo/Canesten
- Marketed Drug Profile - Laboratorios Bago's Medinova Fluomizin
- Marketed Drug Profile - Mayne Pharma's Itragerm/Itraisdin/Lozanoc/Tolsura
- Marketed Drugs - Annual Cost of Therapy
- Pipeline Drugs Overview - Early- to Late-Stage Pipeline Drugs in VVC
- Pipeline Drugs - Overview by Development Stage
- Pipeline Drugs - Overview by MOA
- Pipeline Drugs - Overview by Route of Administration
- Pipeline Drugs - Overview by Molecule Type
- Pipeline Drug Profile - Female Healthcare's (domiphen bromide + miconazole)
- Pipeline Drug Profile - Female Healthcare's (domiphen bromide + miconazole) - Summary
- Pipeline Drug Profile - LimmaTech Biologics' Candi-5V
- Pipeline Drug Profile - LimmaTech Biologics' Candi-5V- Summary
- Pipeline Drug Profile - Jiangsu ProteLight Pharmaceutical and Biotechnology's PL-18
- Pipeline Drug Profile - Cisen Pharmaceutical's WXSH-0102
- Pipeline Drug Profile - Profem's (clotrimazole + diclofenac sodium)
- Pipeline Drugs - PTSR and LoA in Infectious Diseases & VVC
- Pipeline Drugs - PTSR and LoA in VVC
- Clinical Trials in VVC - Historical Overview by Phase
- Clinical Trials in VVC - Historical Overview by Sponsor Type
- Clinical Trials in VVC - Overview by Phase
- Clinical Trials in VVC - Overview by Status
- Clinical Trials in VVC - Overview by Phase for Ongoing and Planned Trials
- Clinical Trials in VVC - Trials with a Virtual Component
- Clinical Trials in VVC - Top Biomarkers by Trial Phase
- Clinical Trials in VVC - Geographic Overview
- Clinical Trials in VVC - Single-Country and Multinational Trials by Region
- Clinical Trials in VVC - Top Sponsors with Breakdown by Phase
- Clinical Trials in VVC - Top Sponsors with Breakdown by Status
- Clinical Trials in VVC - Overview by Endpoint Status
- Clinical Trials in VVC - Overview by Race and Ethnicity of Trial Participants
- Clinical Trials in VVC - Enrollment Data
- Clinical Trials in VVC - Overview of Sites by Geography
- Clinical Trials in VVC - Top 20 Countries for Trial Sites
- Clinical Trials in VVC - Top 20 Sites Globally
- Clinical Trials - Feasibility Analysis: Geography Overview
- Clinical Trials - Feasibility Analysis: Benchmark Models for VVC
- Deals Landscape - Mergers, Acquisitions, and Strategic Alliances in VVC by Region
- Deals Landscape - Recent Mergers, Acquisitions, and Strategic Alliances in VVC
- Commercial Assessment - Key Market Players in VVC
- Future Market Catalysts - Upcoming Market Catalysts in VVC
- Methodology - Sales Forecasts
- Methodology - Pricing and Reimbursement
- Methodology - Phase Transition Success Rate and Likelihood of Approval Analysis
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
